A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Lay Description
Category
- IRB Number
- 20210838HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Sarah Martinez
(210) 450-0569
martinezs23@uthscsa.edu
Charlotte Rhodes
(210) 450-8454
rhodesc1@uthscsa.edu
Sarah Martinez
(210) 450-0569
martinezs23@uthscsa.edu
Charlotte Rhodes
(210) 450-8454
rhodesc1@uthscsa.edu
Principal Investigator
Rebecca Romero